Drugmakers bet billions that targeted radiation could become the next cancer breakthrough

Bristol Myers Squibb, AstraZeneca, Eli Lilly and other drug companies have invested some $10 billion on promising cancer technology behind Novartis’ Pluvicto.

Previous post ‘Like winning the lottery without buying a ticket.’ These people got rich in unexpected ways.
Next post Charles Schwab’s stock rises on uptick in August activity